11th Aug 2020 14:18
Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Names Neil Bell as chief development officer of Avacta Life Sciences Ltd, effective immediately. He will be responsible for late stage pre-clinical and earl clinical development of Avacta's pipeline of 'precision' pro-drugs and affimer immunotherapies. He has 30 years of experience in the drug development industry, working most notably as head of global clinical operations for Teva Pharmaceuticals and as senior vice president as well as head of global clinical operations at Autolus Therapeutics PLC.
Current stock price: 143.50 pence
Year-to-date change: up over 100%; traded at 17.25 pence each on December 31, 2019
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group